Effect of berberine on hyperglycaemia and gut microbiota composition in type 2 diabetic Goto-Kakizaki rats

Figure 2 Body weight and metabolic parameter levels after treatment. A: Comparison of the fasting FBG levels. ^bP < 0.01 vs the model (Mo) group; ^dP < 0.01 vs the metformin (Me) group; B: Comparison of the insulin levels. ^aP < 0.05 vs the Mo group; C: Comparison of the homeostatic model assessment-insulin resistance levels. ^bP < 0.01 vs the Mo group; ^dP < 0.05 vs the Me group; D: Comparison of the glucagon-like peptide-1 levels. ^aP < 0.05 vs the Mo group; E: Comparison of the lipid levels. ^bP < 0.01 vs the Mo group. FBG: Fasting blood glucose; HOMA-IR: Homeostatic model assessment-insulin resistance; GLP-1: Glucagon-like peptide-1; TC: Total cholesterol; TG: Triglycerides; Mo: Model group; Me: Metformin group; Be: Berberine group.